



Milana V. Dolezal, MD, MSci

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Emeryville Multispecialty Clinic**

5800 Hollis St

Emeryville, CA 94608

Tel (510) 806-2100 Fax (510) 974-2428

Bio

BIO

Dr. Dolezal is a board-certified hematologist-oncologist with Stanford Medicine Cancer Center in Emeryville and a clinical associate professor in the Stanford School of Medicine, Division of Oncology.

She strives to work with patients to develop care plans that are comprehensive and personalized achieve the best possible outcomes and quality of life.

Dr. Dolezal also has extensive experience in research and drug development. She previously held positions as a clinical scientist, assistant medical director, and associate medical director in the BioOncology Therapeutics unit of the biotechnology company Genentech.

She has conducted clinical research into fertility preservation in patients with breast cancer, advanced treatments for triple-negative breast cancer, and patients' adherence to anti-cancer therapy. She has co-authored articles on her research findings that appeared in the Journal of Clinical Oncology, Cancer, and other peer-reviewed publications.

She also co-authored the chapter "Progression from Hormone-Dependent to Hormone-Independent Breast Cancer" in the textbook Hormones, Genes and Cancer published by Oxford University Press.

Dr. Dolezal has made presentations to her peers at meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and European Cancer Organisation.

CLINICAL FOCUS

- Medical Oncology
- Sexual Health
- Breast Cancer

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology

HONORS AND AWARDS

- Sponsored Athlete, Zoom Elite Triathlon Team
- Team USA Triathlon Age-Group Division World Championships, Team USA - USA Triathlon
- Ironman Finisher, Ironman Triathlon
- Tour of Hope Rider Across the USA, Tour de Hope
- Speaker at NIH as Tour of Hope Representative and Former NIH Researcher, National Institutes of Health (NIH)
- Research Scholarly Committee, University of Southern California Department of Medicine
- Triathlon and Cycling Coach, Leukemia & Lymphoma Society Team in Training (TNT)
- Foerderer Scholarship for International Study on HIV Education in Africa, International AIDS Society
- President, Medical Students for Choice, Jefferson Medical College
- Gibbon Scholar, Thomas Jefferson Medical College and Graduate School
- Senatorial Scholarship, Maryland
- House of Delegates Scholarship, Maryland Higher Education Commission
- General Honors Program, University of Maryland

PROFESSIONAL EDUCATION

- Medical Education: Sidney Kimmel Medical College Thomas Jefferson University (1999) PA
- Board Certification: Hematology, American Board of Internal Medicine (2007)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2006)
- Fellowship: UCLA Division of Hematology and Oncology (2005) CA
- Residency: USC/LAC Medical Center (2002) CA

Publications

PUBLICATIONS

- **Safety and 5-year survival following treatment with leronlimab plus physician's choice combination therapy in patients with metastatic triple-negative breast cancer**
Tripathy, D., Dolezal, M. V., Abramson, V. G., Chittoria, N., Ehsani, S., Pestell, R. G., Rugo, H. S., Rui, H., Adams, D. L., Meidling, J., Lataillade, M., Lalezari, J. P.
LIPPINCOTT WILLIAMS & WILKINS.2026: e13109
- **Circulating tumor DNA (ctDNA) monitoring of high-risk breast cancer patients: A retrospective descriptive analysis in a community setting.**
Thompson, C., Riaz, F., Dolezal, M. V.
LIPPINCOTT WILLIAMS & WILKINS.2026: e12606
- **Sustained disease-free survival in metastatic triple-negative breast cancer following CCR5 antibody leronlimab and atezolizumab: A case study** *CURRENT PROBLEMS IN CANCER: CASE REPORTS*
Dolezal, M., Khan, O. F., Lalezari, J. P.
2026; 22
- **Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.** *Cancer*
Letourneau, J. M., Wald, K., Sinha, N., Juarez-Hernandez, F., Harris, E., Cedars, M. I., McCulloch, C. E., Dolezal, M., Chien, A. J., Rosen, M. P.
2020; 126 (3): 487-495

- **Psychosocial distress screening and the survivorship care plan in the community oncology setting.**
Dolezal, M. V., Prishtina, M., Ridgley, L., Hart-Inkster, B., Christensen, K., Orange, D.
AMER SOC CLINICAL ONCOLOGY.2016
- **Modeling notch signaling in normal and neoplastic hematopoiesis: global gene expression profiling in response to activated notch expression.** *Stem cells (Dayton, Ohio)*
Ganapati, U., Tan, H. T., Lynch, M., Dolezal, M., de Vos, S., Gasson, J. C.
2007; 25 (8): 1872-80
- **Immunophenotypic and genotypic characterization of progression in follicular lymphomas** *APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY*
Natkunam, Y., Soslow, R., Matolcsy, A. A., Dolezal, M., Bhargava, V., Knowles, D. M., Warnke, R.
2004; 12 (2): 97-104
- **Neurocysticercosis and oncogenesis.** *Archives of medical research*
Del Brutto, O. H., Dolezal, M., Castillo, P. R., García, H. H.
2000; 31 (2): 151-5
- **CLONAL VDJ RECOMBINATION OF THE IMMUNOGLOBULIN HEAVY-CHAIN GENE BY PCR IN CLASSICAL HODGKINS-DISEASE** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Kamel, O. W., Chang, P. P., Hsu, F. J., DOLEZAL, M. V., Warnke, R. A., VANDERIJN, M.
1995; 104 (4): 419-423
- **VIRUS-ASSOCIATED HEMOPHAGOCYTIC SYNDROME CHARACTERIZED BY CLONAL EPSTEIN-BARR-VIRUS GENOME** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
DOLEZAL, M. V., Kamel, O. W., VANDERIJN, M., Cleary, M. L., Sibley, R. K., Warnke, R. A.
1995; 103 (2): 189-194
- **Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.** *Oncogene*
Yano, T., Sander, C. A., Clark, H. M., Dolezal, M. V., Jaffe, E. S., Raffeld, M.
1993; 8 (10): 2741-8